To further address the dependencies of IL-6 on NMD in the overall outcome of tumor immunity triggered by anti-CTLA-4 and anti-PD-1 antibodies, we performed an in vivo experiment in 4T1 tumor-bearing mice combining IL-6 blocking antibody with anti-CTLA-4 and anti-PD-1 antibodies in control tumors or SMG1KD derived tumors. The gene discussed is IL6; the disease is neoplasm.